Skip to content
Screener

Dianthus Therapeutics DNTH Prepaid & Other Current

Prepaid & Other Current at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$4.83B+10.7%
Amgen logo
AmgenAMGN
$4.53B+32.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$3.91M-26.2%
Vor Biopharma logo
Vor BiopharmaVOR
$6.39M+41.6%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$7.44M-28.7%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$4.97M+18.1%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$6.09B+902%
Enterprise value$5.47B+817%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001690585-26-000022
Line itemMarch 31,2026December 31,2025
Cash and cash equivalents$627,667$51,087
Short-term investments483,592353,208
Accounts receivable, net1,23052
Prepaid expenses and other current assets7,4225,091
Total current assets1,119,911409,438
Long-term investments113,868110,135
Property and equipment, net274296
Right-of-use operating lease assets1,2931,337

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dianthus Therapeutics's prepaid & other current?
Dianthus Therapeutics (DNTH) reported prepaid & other current of $7.42M in Q1 2026.
How has Dianthus Therapeutics's prepaid & other current changed year-over-year?
Dianthus Therapeutics's prepaid & other current increased by 9.6% year-over-year, from $6.77M to $7.42M.
What is the long-term trend for Dianthus Therapeutics's prepaid & other current?
Over 5 years (2020 to 2025), Dianthus Therapeutics's prepaid & other current has grown at a 13.6% compound annual growth rate (CAGR), from $2.69M to $5.09M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.

Ask your AI about Dianthus Therapeutics's prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude